EP2983729A1 - Elastic stent graft - Google Patents
Elastic stent graftInfo
- Publication number
- EP2983729A1 EP2983729A1 EP14705440.7A EP14705440A EP2983729A1 EP 2983729 A1 EP2983729 A1 EP 2983729A1 EP 14705440 A EP14705440 A EP 14705440A EP 2983729 A1 EP2983729 A1 EP 2983729A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- stent
- stent graft
- fluoropolymer membrane
- graft
- cover
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012528 membrane Substances 0.000 claims abstract description 115
- 229920002313 fluoropolymer Polymers 0.000 claims abstract description 84
- 239000004811 fluoropolymer Substances 0.000 claims abstract description 84
- 239000002131 composite material Substances 0.000 claims abstract description 82
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims abstract description 69
- 229920001971 elastomer Polymers 0.000 claims abstract description 45
- 239000000806 elastomer Substances 0.000 claims abstract description 45
- -1 polytetrafluoroethylene Polymers 0.000 claims abstract description 21
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims abstract description 18
- 239000004810 polytetrafluoroethylene Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 30
- 239000011148 porous material Substances 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 15
- 230000037303 wrinkles Effects 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 abstract description 24
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 19
- 239000010408 film Substances 0.000 description 16
- 239000002243 precursor Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 238000001878 scanning electron micrograph Methods 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 5
- BLTXWCKMNMYXEA-UHFFFAOYSA-N 1,1,2-trifluoro-2-(trifluoromethoxy)ethene Chemical compound FC(F)=C(F)OC(F)(F)F BLTXWCKMNMYXEA-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 3
- 238000004804 winding Methods 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229920001973 fluoroelastomer Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 238000009864 tensile test Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- DOWJGHMZJRTBBD-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethene;1,1,2-trifluoro-2-(trifluoromethoxy)ethene Chemical compound FC(F)=C(F)F.FC(F)=C(F)OC(F)(F)F DOWJGHMZJRTBBD-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000013147 laser angioplasty Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
Definitions
- the present invention relates generally to medical implants for supporting, maintaining, or repairing a lumen, passageway, or opening in a living body, and more particularly, to a stent having thereon a covering that includes (1 ) an expanded polytetrafluoroethylene (ePTFE) membrane containing serpentine fibrils and (2) an elastomer.
- ePTFE expanded polytetrafluoroethylene
- swipe fibrils means multiple fibrils that curve or turn one way then another.
- controlled retraction refers to causing articles to shorten in length in at least one direction by the application of heat, by wetting with a solvent, or by any other suitable means or combinations thereof in such a way as to inhibit folding, pleating, or wrinkling of the subsequent article visible to the naked eye.
- imbibed or imbibing as used herein is meant to describe any means for at least partially filling at least a portion of the pores of a porous material such as ePTFE or the like.
- elastic refers to the property of a material to be elongated upon the application of a force and that returns to its approximate original dimensions upon the release of the force due to the retraction force of the material.
- elastic refers to the property of a material to be elongated upon the application of a force and that returns to its approximate original dimensions upon the release of the force due to the retraction force of the material.
- increase in stiffness refers the increase in resistance to further elongation once the stop-point is reached.
- the entire device is considered to be “wrinkle-free” if within a 1 cm length of the device, the graft portion is devoid of wrinkles and folds. It is to be noted that the terms “free of folds”, “devoid of folds”, and “fold free” are used interchangeably herein.
- vascular grafts have long been used for vascular repair in humans and animals. These devices are typically flexible tubes of woven or knitted polyethylene terephthalate or porous polytetrafluoroethylene (hereinafter PTFE). Grafts of biological origin have also been used, these being typically fixed human umbilical or bovine arteries. Such conventional vascular grafts usually require invasive surgical methods that expose at least both ends of the segment of the vessel to be repaired. Frequently it is necessary to expose the entire length of the vessel segment. These types of repairs cause major trauma to the patient with corresponding lengthy recovery periods and occasionally, even death.
- PTFE polyethylene terephthalate
- grafts of biological origin have also been used, these being typically fixed human umbilical or bovine arteries.
- Such conventional vascular grafts usually require invasive surgical methods that expose at least both ends of the segment of the vessel to be repaired. Frequently it is necessary to expose the entire length of the vessel segment. These types of repairs cause major trauma to the patient with corresponding lengthy recovery periods and occasionally
- intraluminal vascular grafts in the form of adjustable stent structural supports, tubular grafts, or a combination thereof. These devices are preferably remotely introduced into a body cavity by the use of a catheter type of delivery system. Alternatively, they may be directly implanted by invasive surgery. The intent of these methods is to maintain patency after an occluded vessel has been re-opened using balloon angioplasty, laser angioplasty, atherectomy, roto-ablation, invasive surgery, or a combination of these treatments.
- Intraluminal vascular grafts can also be used to repair aneurysmal vessels, particularly aortic arteries, by inserting an intraluminal vascular graft within the aneurysmal vessel so that the prosthetic device withstands the blood pressure forces responsible for creating the aneurysm.
- intraluminal vascular grafts provide a new blood contacting surface within the lumen of a diseased living vessel.
- the intraluminal graft used may be collapsed and inserted into a body conduit at a smaller diameter and at a location remote from the intended repair site.
- a catheter type of delivery system is then used to move the intraluminal graft into the repair site and then expand its diameter appropriately to conform to the inner surface of the living vessel.
- Various attachment methods including the use of adjustable stents may be used to secure the intraluminal graft at the desired location without the necessity of invasive surgery.
- Stent grafts have been used extensively where external support, such as in the form of rings, spirals, or metal frames with a multiplicity of openings, and the like are required when the application or patient anatomy may exert forces that either could crush or collapse the intraluminal device were it not for the presence of the support.
- a support is also required in situations where the internal pressure on the device would result in undesirable diametric growth of the device were it not for the presence of the support.
- Stent grafts can take many forms and may be constructed of a wide variety of materials including, but not limited to, stainless steel, tantalum, nitinol stent materials and polyurethane, ePTFE, and Dacron cover materials.
- fluoropolymer membranes characteristically possess serpentine fibrils.
- a stent graft that includes (1 ) a stent having a wall with at least one opening, an outer surface, and an inner surface, and (2) a cover affixed to the stent.
- the cover may be affixed to the outer surface and/or the inner surface.
- the cover includes a composite material that includes at least one expanded fluoropolymer membrane and an elastomer.
- the composite material has a stop point at which no further expansion, elongation, or both occur. That is, the composite material can be radially expanded or elongated to a point at which further expansion is inhibited by a dramatic increase in stiffness.
- the expanded fluoropolymer membrane includes serpentine fibrils.
- the fluoropolymer is polytetrafluoroethylene.
- the fluoropolymer membrane may include a
- microstructure of substantially only serpentine fibrils In at least one
- the fluoropolymer membrane may include a plurality of serpentine fibrils.
- the serpentine fibrils have a width of about 1 .0 micron or less.
- the endoprosthetic device expands and contracts radially after deployment into a vessel in a body without the cover infolding into the vessel.
- the cover can remain wrinkle-free when radially expanded at about 80% of the nominal diameter and greater.
- the composite material can be free of wrinkles before loading and after deployment of the endoprosthetic device to a nominal diameter.
- an intraluminal stent graft that includes (1 ) a stent having a wall with at least one opening, an outer surface, and an inner surface and (2) a cover that includes a composite material that contains at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer.
- the serpentine fibrils have a width of about 1 .0 micron or less.
- the cover is provided on at least one surface of the stent and covers at least a portion of the opening.
- the elastomer may be positioned on the fluoropolymer membrane and/or in all or substantially all of the pores of the fluoropolymer membrane.
- the fluoropolymer is polytetrafluoroethylene.
- the cover can be optionally used to cover the outside and/or the inside of the stent.
- the cover possesses good flexibility.
- the composite material has a stop point at which no further expansion occurs. That is, the composite material may be radially expanded to a point at which further expansion is inhibited by a dramatic increase in stiffness.
- the cover can be designed to distend at a relatively low pressure until a predetermined diameter is achieved. Upon reaching that predetermined diameter, significantly higher pressures are required to further distend the stent graft.
- the stent graft has a migration resistance that is similar to devices that contain barbs that penetrate the vessel.
- an intraluminal graft that includes a tubular support member that contains a composite material that includes at least one expanded fluoropolymer membrane and an elastomer where the tubular support has elastic properties in the axial direction of the support.
- the expanded fluoropolymer membrane includes serpentine fibrils.
- the serpentine fibrils have a width of about 1 .0 micron or less.
- the fluoropolymer is polytetrafluoroethylene.
- the elastomer may be present in all or substantially all of the pores of the expanded fluoropolymer membrane.
- the fluoropolymer membrane may include a
- the fluoropolymer membrane includes a plurality of serpentine fibrils.
- the composite material has a stop point at which no further expansion occurs. That is, the composite material can be radially expanded to a point at which further expansion is inhibited by a dramatic increase in stiffness.
- It is a further object of the present invention to provide a method of manufacturing a stent graft that includes (1 ) positioning a cover including a composite material on at least one surface of a stent at a nominal diameter of the stent to form a stent graft and (2) permitting the cover to bond to the stent at substantially room temperature.
- the composite material includes at least one expanded fluoropolymer membrane and an elastomer.
- the cover may be positioned on the outer surface and/or the inner surface of the stent.
- An adhesive may be applied to the stent prior to positioning the cover on the stent.
- the expanded fluoropolymer membrane includes a microstructure of substantially only serpentine fibrils.
- fluoropolymer membrane may include a plurality of serpentine fibrils.
- the serpentine fibrils have a width of about 1 .0 micron or less.
- an intraluminal stent graft that includes (1 ) a stent having a wall with at least one opening, an outer surface, and an inner surface and (2) a cover including a composite material that exhibits an increase in stiffness when expanded to at least about 14 mm.
- the cover is provided on at least one of the outer surface and the inner surface and covers at least a portion of the at least one opening.
- the composite material includes at least one expanded fluoropolymer membrane and an elastomer.
- the expanded fluoropolymer may include a microstructure of serpentine fibrils.
- the fluoropolymer membrane may include a plurality of serpentine fibrils. The serpentine fibrils have a width of about 1 .0 micron or less.
- an intraluminal graft that includes a tubular support member including (1 ) a composite material exhibiting an increase in stiffness when expanded to at least about 14 mm and (2) an elastomer.
- the tubular support member has elastic properties in the axial direction of the tubular support member.
- an endoprosthetic device containing the composite material is free or substantially free of folds when radially expanded to about 80% of its nominal diameter.
- a stent graft can be manufactured at the stent nominal diameter.
- endoprosthetic devices utilizing the inventive elastomeric composite material demonstrate improved migration resistance. It is another advantage of the present invention that the stent graft can be implanted undersized with respect to a nominal diameter without having material infolding.
- an elastic stent graft is formed that has regions of compression and extension without material folding.
- the stent graft may have elastic properties longitudinally, radially, or both longitudinally and radially.
- Figure 1 is a schematic illustration of an exemplary, idealized serpentine fibril
- Figure 2a is a scanning electron micrograph of the surface of an inventive elastomeric composite material taken at 5000x;
- Figure 2b is a scanning electron micrograph of the surface of the inventive elastomeric composite material of Figure 2a taken at 5000x after subsequent elongation;
- Figure 3 is a load versus extension curve corresponding to an axially wrapped stent according to the present invention.
- Figure 4 is a schematic illustration of an exemplary elastic stent graft according to the instant invention.
- Figure 4a is a schematic illustration depicting a portion of the elastic stent graft of Figure 4 showing a wire coated with an adhesive and the
- Figure 5 is a scanning electron micrograph of the surface of a helically wrapped tube with the copolymer partially removed taken at 5000x;
- Figure 6 is a pressure vs. diameter curve corresponding to a helically wrapped tube according to the present invention.
- the present invention is directed to a stent having thereon a graft that includes a composite material including (1 ) an expanded polytetrafluoroethylene (ePTFE) membrane containing serpentine fibrils and (2) an elastomer.
- ePTFE expanded polytetrafluoroethylene
- the elastomer may be positioned on the ePTFE membrane and may also, or alternatively, be located in at least a portion of the pores of the ePTFE
- the elastomer may be present in all or substantially all of the pores of the ePTFE membrane.
- the term "substantially all of the pores” as used herein is meant to denote that the elastomer is present in at least a portion of all or nearly all of the pores of the ePTFE membrane.
- the stent includes a fluoropolymer membrane.
- the stent graft and tubes of the invention may be employed in any body conduit or vessel, including arteries and veins.
- Stent covers enable the exclusion of aneurysms and inhibit the passage of body fluids across the walls of the stent.
- the stent cover can be optionally used to cover the outside and/or the inside of the stent or other support structures. It is to be understood that a tube formed of the inventive composite material can be used without covering a stent.
- One benefit of the instant invention is that the elastic properties in the radial direction of a stand alone tube (which could serve as an intraluminal graft) or the graft portion of the stent graft remains fold-free when radially contracted about 80%, or conversely, the graft portion of the stent graft is fold-free when radially expanded to about 80% and greater.
- a stent graft or tube formed with the inventive composite material (cover) can expand and/or contract radially after being deployed without having or reducing the amount of material infolding, thereby minimizing obstructions that can cause thrombosis.
- folds in the graft portion may serve as sites of thrombus accumulation that can ultimately result in total occlusion of the device.
- fold-free is the reduction or elimination of thrombic depositions.
- the entire device is considered to be "wrinkle-free" if within a 1 cm length of the device, the graft portion is devoid of wrinkles and folds when viewed by the naked eye. It is to be noted that 1 cm length of the device should be used unless the entire length of the device is less than 1 cm.
- the entire device should be utilized to determine if the device is "wrinkle-free.” Consequently, should the stent graft be implanted undersized, no folds are present in the cover. Furthermore, if needed, the covered stent can be elastically expanded beyond the nominal stent diameter (i.e., the labeled diameter) when the cover is constructed to have a stop point greater than the nominal diameter.
- a tube or stent graft can be constructed such that the elastic properties are present in the longitudinal direction of the device.
- a longitudinally stretchable stent graft prevents infolding of the graft into the lumen as discussed above.
- longitudinally stretchable stent graft is that when the stent graft is presented with a tortuous path, the inventive stent graft is able to bend without kinking when placed in a body conduit arch. More specifically, the tension side of the bend can stretch and the compression side of the bend can compress without wrinkling the composite material (cover). The stretching of the composite material permits for a smooth flow through the stent graft as little or no wrinkling occurs.
- the composite material may also be used to construct circumferentially-, helically-, or axially- oriented tubes and covers, as well as combinations thereof.
- the term "axial” is interchangeable with the term “longitudinal.”
- elasticity is imparted in both the longitudinal and circumferential directions.
- the cover can be formed prior to application to a stent (i.e., a separate cover can be made in the shape of a tube from the composite material).
- the cover can be formed after the composite material has been applied to the stent, after which the composite material is bonded both to itself and to the stent.
- Stent grafts with minimal or no material infolding are able to accommodate the natural tapering of vessels to a greater degree than conventionally known devices. Additionally, tubes and stent grafts formed from the inventive composite material have improved migration resistance compared to conventional devices.
- the cover of the present invention is unique in that it is fold-free or substantially fold-free as implanted; e.g., the cover can be substantially fold-free when radially expanded to about 80% and up to about 100% of the nominal diameter or greater.
- the cover is unique in that it exhibits a sharp increase in stiffness at a predetermined diameter. This latter property creates a "stop-point" beyond which increased balloon pressure does not further increase the covered stent diameter.
- One advantage of the feature of the stop point is that the stent graft does not itself become aneurismal.
- the tubes and stent grafts of the present invention can be designed to have a stop point in either a radial or axial direction.
- an additional benefit of the present invention is that the tube or the cover portion of a stent graft can be designed to distend at a relatively low pressure until a predetermined diameter is achieved. Upon reaching that diameter, significantly higher pressures are required to further distend the tube or stent graft. In other words, the slope of the diameter versus pressure curve decreases dramatically once the pre-determined diameter is reached.
- Pressure-diameter curves relating to tubes and covered stents of the present invention exhibit an inflection point due to the change in slope (which is directly related to the stiffness) upon reaching a diameter referred to herein as the stop point.
- Figure 6 is a pressure vs. diameter curve of an article according to the present invention, in this case a tube, in which the intersection of two tangent lines depicts the stop point of the article.
- An estimate of the stop point may be determined in the following manner. The slope of the pressure-diameter curve prior to reaching the stop point can be approximated by drawing a straight line tangent to the curve, shown as line 30 in Figure 6.
- the slope of the pressure-diameter curve beyond the stop point can be approximated by drawing a straight line tangent to the curve, shown as line 40 in Figure 6.
- the diameter corresponding to the intersection of the two tangent lines, depicted by reference numeral 50, is an estimation of the stop point for the article.
- a cover formed of the composite material can be positioned on the outer and/or inner surface of the stent with the stent at the nominal stent diameter.
- the composite material is at least partially elongated upon application to the stent (e.g., by wrapping the material around the stent) at its nominal diameter, or larger than nominal diameter.
- the composite material may be stretched until the composite material is at least partially elongated prior to or during the positioning of a tubular cover on the stent.
- a cover having a substantially smaller diameter than the nominal diameter of the stent can be employed to cover the stent at least partially due to the elasticity of the composite material.
- the range within which the cover can be wrinkle-free can be at least about 80% of the nominal diameter and greater
- the amount of tension applied to the composite material when forming can be adjusted to adjust the elastic range (or wrinkle-free range) of the cover and the stop point. For example, if the composite material is applied to a stent at nominal diameter with near complete elongation, the stop point will be approximately the nominal diameter, and the amount of compaction permitted while remaining wrinkle free and the amount of expansion permitted while remaining wrinkle free is at a maximum for that composite material. However, if the same composite material is applied to the same stent with only partial elongation, the stop point will be at a diameter greater than the nominal diameter, and the amount of compaction and expansion permitted while remaining wrinkle free is less than the former.
- the cover can be bonded to the stent at or substantially at room
- An adhesive such as an adhesive copolymer, may be applied to the stent prior to positioning the cover on the outer surface and/or the inner surface of the stent to bond the cover to the stent.
- Another advantage of the present invention is the ability of the stent graft to be expanded in situ to dislodge a clot or other adhesion on the inner surface.
- the at least partially occluded covered stent may be expanded to a larger diameter through the use of a balloon catheter, thereby dislodging the stenotic material.
- a protective measure could be used to capture the stenotic material to prevent stroke, thrombosis, or other unwanted, deleterious side effects.
- the covered stent Upon release of the pressure of the balloon, the covered stent returns at least substantially to its previous diameter without wrinkling.
- fluoropolymer membranes that exhibit high elongation while substantially retaining the strength properties of the fluoropolymer membrane are utilized as the cover material.
- Such membranes characteristically possess serpentine fibrils, such as the idealized serpentine fibril exemplified in Figure 1 .
- a serpentine fibril curves or turns generally one way in the direction of arrow 10 then generally another way in the direction of arrow 20. It is to be understood that the amplitude, frequency, and periodicity of the serpentine-like fibrils as exemplified in Figure 1 may vary.
- the fluoropolymer membranes are expanded fluoropolymer membranes.
- Non-limiting examples of expandable fluoropolymers include, but are not limited to, expanded PTFE, expanded modified PTFE, and expanded copolymers of PTFE.
- Patents have been filed on expandable blends of PTFE, expandable modified PTFE, and expanded copolymers of PTFE, such as, for example, U.S. Patent No. 5,708,044 to Branca; U.S. Patent No. 6,541 ,589 to Baillie; U.S. Patent No. 7,531 ,61 1 to Sabol et al. ; U.S. Patent Application No. 1 1 /906,877 to Ford; and U.S. Patent Application No. 12/410,050 to Xu et al.
- the high elongation is enabled by forming relatively straight fibrils into serpentine fibrils that substantially straighten upon the application of a force in a direction opposite to the compressed direction.
- the creation of the serpentine fibrils can be achieved through a thermally-induced controlled retraction of the expanded polytetrafluoroethylene (ePTFE), through wetting the article with a solvent, such as, but not limited to, isopropyl alcohol or Fluorinert ® (a
- the retraction of the article does not result in visible pleating, folding, or wrinkling of the ePTFE, unlike what occurs during mechanical compression.
- the retraction also can be applied to very thin membranes, unlike known methods. During the retraction process, the fibrils not only become serpentine in shape but also may also increase in width.
- the precursor materials can be biaxially expanded ePTFE membranes.
- materials such as those made in accordance with the general teachings of U.S. Patent No. 7,306,729 to Bacino, et al. are suitable precursor membranes, especially if small pore size articles are desired. These membranes may possess a microstructure of substantially only fibrils.
- the precursor membrane may or may not be amorphously locked. Additionally, the precursor membrane may be at least partially filled, coated, or otherwise combined with additional materials.
- the precursor membrane may be restrained in one or more directions during the retraction process in order to prescribe the desired amount of elongation of the final article.
- the amount of elongation is directly related to, and is determined by, the amount of retraction.
- retraction can be achieved in a uniaxial tenter frame by positioning the rails at a distance less than the width of the precursor membrane prior to the application of heat or solvent or both.
- one or both of the sets of grips, pins, or other suitable attachment means can similarly be positioned at a distance less than the dimensions of the precursor membrane. It is to be appreciated that these retraction means differ from the mechanical compression taught by the House and Sowinski patents noted above.
- the expanded fluoropolymer membrane possesses serpentine fibrils.
- the retracted membranes may possess a microstructure of substantially only serpentine fibrils. In at least one
- the fluoropolymer membranes include a plurality of serpentine fibrils.
- the phrase "plurality of serpentine fibrils” is meant to denote the presence of 2 or more, 5 or more, 10 or more, or 15 or more serpentine fibrils in the fluoropolymer membrane within a field of view as taught below.
- the serpentine fibrils have a width of about 1 .0 micron or less, and in some embodiments, about 0.5 microns or less. In one embodiment, the serpentine fibrils have a width from about 0.1 to about 1 .0 microns, or from about 0.1 to about 0.5 microns.
- the precursor membranes described above can be imbibed with an elastomeric material prior, during, or subsequent to retraction to form a
- Suitable elastomeric materials include, but are not limited to, PMVE- TFE (perfluoromethylvinyl ether-tetrafluoroethylene) copolymers, PAVE-TFE (perfluoro (alkyl vinyl ether)-tetrafluoroethylene) copolymers, silicones, polyurethanes, and the like. It is to be noted that PMVE-TFE and PAVE-TFE are fluoroelastomers. Having generally described this invention, a further understanding can be obtained by reference to certain specific examples illustrated below which are provided for purposes of illustration only and are not intended to be all inclusive or limiting unless otherwise specified.
- Tensile break load was measured using an INSTRON 122 tensile test machine equipped with flat-faced grips and a 0.445 kN load cell. The gauge length was about 5.08 cm and the cross-head speed was about 50.8 cm/min. The sample dimensions were about 2.54 cm by about 15.24 cm. For highest strength measurements, the longer dimension of the sample was oriented in the highest strength direction. For the orthogonal MTS measurements, the larger dimension of the sample was oriented perpendicular to the highest strength direction. Each sample was weighed using a Mettler Toledo Scale Model AG204, then the thickness was measured using the Kafer FZ1000/30 snap gauge; alternatively, any suitable means for measuring thickness may be used. The samples were then tested individually on the tensile tester.
- MTS maximum load/cross-section area * (bulk density of PTFE)/ (density of the porous membrane), where the bulk density of the PTFE was taken to be about 2.2 g/cm 3 .
- measurements should be made for serpentine fibrils that are substantially separated from each other and do not band together or otherwise form series of fibrils paralleling each other within the membrane.
- a line is drawn through the SEM image to bisect it.
- the SEM image should be of sufficient magnification such that at least 5 serpentine fibrils and not more than 20 serpentine fibrils are clearly visible within the SEM image.
- the width of the first five consecutive serpentine fibrils that intersect the bisecting line is measured. The measurements are made where the fibril intersects the bisecting line. Next, the five measurements are averaged and the average measurement is recorded.
- the elastomer can be dissolved or degraded and subsequently rinsed away using an appropriate solvent in order to measure or examine desired properties.
- the fluoroelastomer component of a tube or a stent cover as described in Examples 2-5 can be partially or substantially removed to enable SEM imaging of the ePTFE structure.
- the sample is submerged in 95 g of Fluorinert® Electronic Liquid FC-72 (3M Inc., St. Paul, MN) and allowed to soak without agitation. After approximately one hour, the fluorinated solvent is poured off and replaced with 95 g of fresh solvent. This process is repeated for a total of 5 soaking cycles, the first 4 cycles for approximately 1 hour, and the 5th cycle for approximately 24 hours.
- the sample can also be agitated using an ultrasonic cleaner (e.g. Branson 200 Ultrasonic Cleaner (Model - B200)). Pressure vs. Diameter Test
- a pressure versus diameter curve is created by radially expanding a tube or covered stent using an inflation syringe to pressurize a balloon catheter.
- the tube or covered stent is positioned over the balloon catheter in its deflated state.
- the tube or covered stent diameter is measured at 1 ATM intervals using a laser micrometer.
- a 14mm balloon diameter with a 20mm balloon length and a 0.035 inch guide wire Peripheral Dilation Catheter (Agilitrac, Abbott Vascular, Santa Clara, CA) and a BasixTM COMPAK (Merit Medical, South Jordan, UT) inflation syringe were used.
- the handle on the inflator was slowly turned while the change in pressure as indicated on the dial was observed.
- the balloon was then inflated to 2 atmospheres (ATM) of pressure.
- the stent easily continued to expand, causing the pressure to drop.
- the inflation was continued until the pressure of 2 ATM was maintained.
- the stent was then inflated at 1 ATM intervals and the diameters at those pressures once pressure equilibrated were recorded. Inflation was continued until 7 atmospheres was achieved, which was 1 ATM below the rated burst pressure of the balloon.
- the tube diameter was recorded at each 1 ATM interval using a laser micrometer (LaserMikeTM Dayton OH).
- the axial elongation test is performed by elongating a sample in a tensile testing machine at a constant crosshead speed. The gage length of the sample and the crosshead speed are recorded. The intent of the test is to determine the stop point of a sample, should one exist.
- the load-extension curves relating to composite materials and covered stents and tubes of the present invention exhibit an inflection point due to the change in slope upon reaching a length referred to as the stop point.
- An estimate of the stop point is determined in the following manner.
- the slope of the load-extension curve prior to reaching the stop point can be approximated by drawing a straight line tangent to the curve.
- the slope of the load-extension curve beyond the stop point can be approximated by drawing a straight line tangent to the curve.
- An estimate of the stop point is the extension
- a roll of precursor membrane where the length direction corresponded with the weakest direction of the membrane was restrained in the clamps of a heated, uniaxial tenter frame and fed into the heated chamber of the tenter frame.
- the oven temperature was set to about 270 °C.
- the rails of the tenter frame within the heated chamber were angled inward in order to allow membrane shrinkage to about 39% of its original width in response to the heat.
- the line speed was set to provide a dwell time of about 1 .5 minutes within the heated chamber.
- the initial and final widths of the membrane were 1625 mm and 632 mm, respectively.
- a copolymer comprising tetrafluoroethylene (TFE) and perfluoro(methyl vinylether) (PMVE) as described in U.S. Patent No. 7,049,380 to Chang, et al. was obtained with a PMVE/TFE ratio of 2:1 .
- the copolymer was extruded at about 350 °C into a thin film.
- the extruded elastomer was fed onto the surface of the retracted membrane and spooled with a 0.064 mm thick high density polyethylene release film.
- the elastomeric composite material is shown in Figure 2a, a SEM of the surface of the membrane opposing the extruded elastomer, taken at 5,000x magnification.
- a length of the elastomeric composite material was stretched by hand to about 78% of the original length.
- the fibrils were seen to have a serpentine shape as indicated in Figure 2b, a SEM of the surface of the membrane opposing the extruded elastomer, taken at 5,000x magnification.
- a circumferentially covered stent was constructed in the following manner. Nitinol wire (600315-18, Fort Wayne Metals, Fort Wayne, IN) was obtained and formed into a stent by winding the wire onto a winding mandrel with appropriately located pins. The stent was 10 cm long and 10 mm in diameter.
- Fluoroinert ® (3M Fluoroinert, 3M Specialty Chemicals Division, St. Paul, MN) was obtained and combined to form a solution.
- the stent was removed from the winding mandrel and dipped into the solution.
- the stent was air dried then placed onto a 10 mm mandrel that had a covering of Kapton film (Lot # B4N0C38500ADD, E. I. du Pont de Nemours and Company, Wilmington, DE).
- Kapton film Lipton film
- One end of the mandrel was secured inside the chuck of a drill.
- the elastomeric composite material was cut to about 100 mm in width. It was noted that the length direction of the composite material was the direction that possessed the elastomeric properties.
- the composite material was circumferentially applied to the stent such that the elastic direction of the material was tangent to the axial direction of the stent.
- the elastomer side of the composite material was applied to the stent with pressure and was secured to the stent under tension due to the tackiness of the elastomer.
- Tension was applied to the composite material to elongate it. The amount of tension was sufficient to exceed the retraction force without disrupting the material but lower than the stop point.
- the drill rotated the mandrel until one composite material layer was wrapped onto the stent.
- a compression wrap was applied to the covered stent in the following manner.
- FIG. 4 is a schematic illustration of a cross- sectional view of an exemplary elastic stent graft 100 according to the instant invention.
- Figure 4a schematically depicts the wire 1 10 coated with an adhesive 120 and the composite material 130 circumferentially applied to the stent.
- An axially covered stent was made as described in Example 2 with the following exceptions.
- the composite material was applied such that the direction of the film possessing the elastomeric properties was in the axial direction of the stent.
- FIG. 3 is a load vs. extension curve corresponding to the axially wrapped stent showing the stop point 80 at about 30 mm, where tangent lines 60, 70 intersect.
- the stent graft recovered to approximately its original length upon removal of the tensile force without substantial wrinkling.
- Example 5 An axially wrapped tube was made in accordance with the process described in Example 2 with the following exceptions. A tube was constructed without involving a stent. The axial elongation test described above demonstrated that the tube axially elongated and incorporated a stop point. The tube recovered to approximately its original length upon removal of the tensile force. Example 5
- a helically wrapped tube was made in accordance with the process described as follows.
- the composite material was slit to about 100 mm wide.
- a helically wrapped tube was made by first wrapping a Kapton film covering ((Lot # B4N0C38500, E. I. du Pont de Nemours and Company, Wilmington, DE)) over a 10 mm stainless steel mandrel and then wrapping one layer of the composite material, with the elastomer side facing outward, on top of the Kapton film at an angle of approximately 45 degrees relative to the
- Kapton film covering ((Lot # B4N0C38500, E. I. du Pont de Nemours and Company, Wilmington, DE)
- the helically wrapped tube had two layers of composite material, one layer at 45 degrees relative to the longitudinal axis and another layer at 135 degrees relative to the longitudinal axis.
- a compression wrap was applied to the outer layer in the following manner.
- a layer of Kapton film was helically wrapped over the outermost composite material, followed by an ePTFE film applied under tension to ensure uniform contact between the composite film layers.
- the resulting assembly was placed in an oven set to 50 °C for approximately 24 hours to bond the two layers of the composite material to each other.
- the coverings and helically wrapped tube were removed from the mandrel and the coverings were removed from the tube.
- the resulting helically wrapped tube was 10 cm long and 10 mm in diameter.
- the tube recovered to approximately its original length upon removal of the tensile force.
- Figure 6 is a pressure vs. diameter curve corresponding to the helically wrapped tube.
- the pressure vs. diameter test described above demonstrated that the tube had a stop point at about 14 mm.
- the tube recovered to approximately its original diameter upon removal of the internal pressure.
- the fibrils of the membrane were noted to have a serpentine shape as shown in Figure 5, a scanning electron micrograph of the surface of helically wrapped tube with the copolymer partially removed taken at 5000x.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/755,481 US9931193B2 (en) | 2012-11-13 | 2013-01-31 | Elastic stent graft |
| PCT/US2014/013496 WO2015116045A1 (en) | 2014-01-29 | 2014-01-29 | Elastic stent graft |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2983729A1 true EP2983729A1 (en) | 2016-02-17 |
Family
ID=55071273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14705440.7A Withdrawn EP2983729A1 (en) | 2013-01-31 | 2014-01-29 | Elastic stent graft |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2983729A1 (en) |
| HK (1) | HK1220147A1 (en) |
-
2014
- 2014-01-29 EP EP14705440.7A patent/EP2983729A1/en not_active Withdrawn
- 2014-01-29 HK HK16108266.2A patent/HK1220147A1/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2015116045A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1220147A1 (en) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331089A1 (en) | Elastic stent graft | |
| AU2007243560B2 (en) | Expandable covered stent with wide range of wrinkle-free deployed diameters | |
| JP5731450B2 (en) | Expandable stent with a wrinkle-free elastic cover | |
| AU2012340060B2 (en) | Lattice | |
| EP2983729A1 (en) | Elastic stent graft | |
| WO2015116045A1 (en) | Elastic stent graft | |
| AU2018200735B2 (en) | Endoprosthesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150714 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20160730 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1220147 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1220147 Country of ref document: HK |